Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $194.00

Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) had its price objective hoisted by Citigroup from $184.00 to $194.00 in a research note released on Wednesday,Benzinga reports. Citigroup currently has a buy rating on the stock.

Other equities research analysts have also issued research reports about the company. UBS Group set a $137.00 price target on Mirum Pharmaceuticals in a research report on Thursday, August 27th. Cantor Fitzgerald increased their price objective on shares of Mirum Pharmaceuticals from $155.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. Weiss Ratings lowered shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 22nd. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Finally, Stifel Nicolaus boosted their price objective on shares of Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $155.56.

Get Our Latest Research Report on MIRM

Mirum Pharmaceuticals Stock Up 0.7%

Shares of MIRM stock opened at $93.99 on Wednesday. The firm’s 50 day moving average price is $88.79 and its two-hundred day moving average price is $98.41. The company has a quick ratio of 1.98, a current ratio of 2.07 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals has a 52-week low of $63.23 and a 52-week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.38). The company had revenue of $185.72 million for the quarter, compared to the consensus estimate of $178.07 million. Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. Mirum Pharmaceuticals’s quarterly revenue was up 39.6% on a year-over-year basis. During the same quarter last year, the business posted $0.05 EPS. As a group, equities analysts forecast that Mirum Pharmaceuticals will post -1.47 EPS for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other news, Director Laura Brege sold 14,167 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $94.21, for a total value of $1,334,673.07. Following the completion of the sale, the director directly owned 15,703 shares in the company, valued at $1,479,379.63. This trade represents a 47.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Jolanda Howe sold 40,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the transaction, the senior vice president owned 1,274 shares in the company, valued at approximately $127,400. The trade was a 96.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 104,825 shares of company stock valued at $10,160,873. Corporate insiders own 8.32% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Several hedge funds have recently bought and sold shares of MIRM. Steward Partners Investment Advisory LLC boosted its stake in Mirum Pharmaceuticals by 87.8% during the third quarter. Steward Partners Investment Advisory LLC now owns 20,123 shares of the company’s stock valued at $1,720,000 after buying an additional 9,409 shares during the period. HighVista Strategies LLC grew its holdings in shares of Mirum Pharmaceuticals by 79.0% during the 3rd quarter. HighVista Strategies LLC now owns 26,660 shares of the company’s stock valued at $2,279,000 after purchasing an additional 11,768 shares during the last quarter. Bleakley Financial Group LLC purchased a new position in shares of Mirum Pharmaceuticals in the third quarter worth about $1,128,000. Impax Asset Management Group plc purchased a new position in shares of Mirum Pharmaceuticals in the third quarter worth about $8,548,000. Finally, Ground Swell Capital LLC bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at about $564,000.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

Featured Stories

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.